Get Adobe Flash player


Аuthors: A. A. Antoniv

Pages: 308–314



The increase in the frequency of nonalcoholic steatohepatitis (NASH) comorbid course on the background of obesity and chronic kidney disease (CKD) in people of working age in Ukraine and in the world necessitates conducting research on mechanisms of mutual burden and finding new factors for the progression pathogenesis of this comorbidity.

The purpose of the study was to establish the mutual burden and progression mechanisms of non-alcoholic steatohepatitis and chronic kidney disease in obese patients based on the study of protein and carbohydrate-protein components of the extracellular matrix, lipid profile of the blood, and functional state of the endothelium.

Material and methods. 114 patients with NASH were examined on the background of degree І-ІІ obesity, including: 52 patients with NASH (group 1) (without accompanying CKD), 62 patients with NASH with comorbid CKD, І-ІІ stage (group 2). The average age of patients was (45.8 ± 3.81) years. The control group consisted of 20 practically healthy persons (PHP) of the corresponding age and sex.

Results. We studied the dynamics of patients with non-alcoholic steatoatepatitus (NASH) with comorbid obesity and chronic kidney disease, І-ІІ stage (CKD), the role of hydrogen sulfide in the mechanisms of mutual burden and progression of comorbid diseases: hyperlipidemia, hyperproduction of extracellular matrix components (protein-bound and free hydroxyproline, glycosaminoglycans, fibronectin, hexosamines, sialic acids), osteoporotic proteins, proteinase-inhibitory imbalances (activation of proteolysis, collagenolysis), endothelial dysfunction (imbalance in generating nitrogen monoxide, endothelin-1, homocysteine).

Conclusions. In patients with NASH on the background of obesity, a significant increase in the synthesis of collagen and glycoproteins was observed, which was accompanied by an ineffective resorption of newly formed collagen due to inhibition of collagenolysis (CLA) on the background of proteinase inhibitors (α2-MG) activation, which was accompanied by hyperproduction of the growth factor fibroblasts, homocysteine, endothelin-1, deficiency in the liberation of hydrogen sulfide and nitrogen monoxide. Under the conditions of the comorbidity of NASH with the CKD of the 1st and 2nd stages, both collagen synthesis and resorption are activated, but the processes of anabolism prevail in spite of the compensatory activation of collagenolysis, with a significant hyperproduction of actinic-phase proteins, fibronectin, glycosaminoglycans, fibroblast growth factor and increased degradation of the extracellular matrix fucoglycoproteins and lead to progressive fibrosis of the liver and disturbance of its functions.

Keywords: nonalcoholic steatohepatitis, chronic kidney disease, obesity, hydrogen sulfide, endothelial dysfunction.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text


  1. Athyros V, Tziomalos K, Katsiki N et al. [Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease; an update.]. World J. Gastroenterol. 2015. 21: 6820–6834.
  2. Fujii H, Kawada N. [Inflammation and fibrogenesis in steatohepatitis]. J. Gastroenterol. 2012;47(3): 215-225. doi: 10.1007/s00535-012-0527-x.
  3. Farrell GC, van Rooyen D, Gan L, Chitturi S. [NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications]. Gut Liver. 2012;6(2):149-171. doi: 10.5009/gnl.2012.6.2.149.
  4. Pagadala MR, McCullough AJ. [The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis]. Clin. Liver Dis. 2012;16(3):487-504. doi: 10.1016/j.cld.2012.05.006.
  5. Day CP, Anstee QM, Targher G. [Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis]. Nat. Rev. Gastroenterol. Hepatol. 2013;10:330-44. doi: 10.1038/nrgastro.2013.41.
  6. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA NASH Clinical Research Network (CRN). [Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings]. Hepatology. 2011;53:810–820. doi: 10.1002/hep.24127.
  7. Fan HN, Chen NW, Shen WL et al. [Endogenous hydrogen sulfide is associated with angiotensin II type 1 receptor in a rat model of carbon tetrachloride-induced hepatic fibrosis]. Mol. Med. Rep. 2015. 12 (3): 3351-3358. doi: 10.3892/mmr.2015.3873
  8. Khukhlina OS, Mandryk OIe. Nealkoholnyi steatohepatyt ta hipertonichna khvoroba: osoblyvosti komorbidnoho perebihu, optymizovani pidkhody do likuvannia: Monohraffia [Non-alcoholic steatohepatitis and hypertension: features of the comorbid course, optimized approaches to treatment]. Chernivtsi: Ukraine, 2014. 204 p.
  9. Fan HN, Wang HJ, Yang-Dan CR et al. [Protective effects of hydrogen sulfide on oxidative stress and fibrosis in hepatic stellate cells]. Mol. Med. Rep. 2013. 7 (1): 247-253.
  10. Fiorucci S, Distrutti E, Cirino G, Wallace J L. [The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology. 2006. 131 (1): 259–271.
  11. Guo C, Liang F, Shah Masood W, Yan X. [Hydrogen sulfide protected gastric epithelial cell from ischemia/reperfusion injury by Keap1 s-sulfhydration, MAPK dependent anti-apoptosis and NF-κB dependent anti-inflammation pathway]. European Journal of Pharmacology. 2014. 725 (1): 70–78.
  12. Han YP, Zhou L, Wang J et al. [Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen]. The Journal of Biological Chemistry. 2004. 279 (6): 4820–4828.
  13. Kajimura M, Fukuda R, Bateman RM et al. [Interactions of Multiple Gas-Transducing Systems: Hallmarks and Uncertainties of CO, NO and H2S Gas Biology]. Antioxidants & Redox signaling. 2010. 13: 57-193.
  14. Kim D, Kim WR, Kim HJ, Therneau TM [Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States]. Hepatology. 2013. 57: 1357–1365.
  15. Marcuccilli М, Chonchol М. [NAFLD and Chronic Kidney Disease]. Int. J. Mol. Sci. 2016. 17 (562): 3-15. doi:10.3390/ijms17040562.